Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of gefitinib on warfarin antithrombotic activity.
Arai S, Mitsufuji H, Nishii Y, Onoda S, Ryuge S, Wada M, Katono K, Iwasaki M, Takakura A, Otani S, Yamamoto M, Yanaihara T, Yokoba M, Kubota M, Katagiri M, Fukui T, Kobayashi H, Yanase N, Hataishi R, Masuda N. Arai S, et al. Among authors: masuda n. Int J Clin Oncol. 2009 Aug;14(4):332-6. doi: 10.1007/s10147-008-0871-2. Epub 2009 Aug 25. Int J Clin Oncol. 2009. PMID: 19705244
Drug interaction between gefitinib and warfarin.
Onoda S, Mitsufuji H, Yanase N, Ryuge S, Kato E, Wada M, Ishii K, Hagiri S, Yamamoto M, Yokoba M, Yanaihara T, Kuboto M, Takada N, Katagiri M, Abe T, Tanaka N, Kobayashi H, Masuda N. Onoda S, et al. Among authors: masuda n. Jpn J Clin Oncol. 2005 Aug;35(8):478-82. doi: 10.1093/jjco/hyi122. Epub 2005 Jul 8. Jpn J Clin Oncol. 2005. PMID: 16006576
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T, Yokoba M, Onoda S, Yamamoto M, Ryuge S, Hagiri S, Katagiri M, Wada M, Mitsufuji H, Kubota M, Arai S, Kobayashi H, Yanase N, Abe T, Masuda N. Yanaihara T, et al. Among authors: masuda n. Cancer Chemother Pharmacol. 2007 Mar;59(4):419-27. doi: 10.1007/s00280-006-0279-5. Epub 2006 Jul 11. Cancer Chemother Pharmacol. 2007. PMID: 16832665 Clinical Trial.
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K; Thoracic Oncology Research Group Study 0301. Onoda S, et al. Among authors: masuda n. J Clin Oncol. 2006 Dec 1;24(34):5448-53. doi: 10.1200/JCO.2006.08.4145. J Clin Oncol. 2006. PMID: 17135647 Clinical Trial.
1,176 results